Mode
Text Size
Log in / Sign up

Meta-analysis shows HIV prevalence is 50% higher in transgender women than cis-MSM in sub-Saharan Africa.

Meta-analysis shows HIV prevalence is 50% higher in transgender women than cis-MSM in sub-Saharan Af…
Photo by Brian McGowan / Unsplash
Key Takeaway
Note the 50% higher HIV prevalence in transgender women versus cis-MSM in sub-Saharan Africa based on observational survey data.

This meta-analysis aggregated data from 21 observational studies conducted in sub-Saharan Africa between 2010 and 2022. The analysis included 8,476 transgender women and 24,102 cisgender men who have sex with men (cis-MSM). The primary objective was to compare HIV prevalence between these groups and assess correlations with broader population data.

Median HIV prevalence was 23.5% (interquartile range 11.5-39.8%) among transgender women, compared to 16.2% (interquartile range 8.1-26.8%) among cis-MSM. The HIV prevalence ratio was 1.48 (95% CI 1.25-1.76), indicating that HIV prevalence was 50% higher in transgender women. Additionally, HIV prevalence in transgender women was highly correlated with that of cis-MSM (R² = 0.60) but poorly correlated with the total population (R² = 0.01).

Safety and tolerability data were not reported, as the study analyzed survey-based prevalence rather than treatment outcomes. Key limitations include the reliance on bio-behavioural surveys focused on determinants of infection rather than distinct treatment uptake or risk behaviors specific to transgender populations. Data to guide HIV programmes are severely limited for transgender people.

The study underscores the need for HIV services addressing the disproportionate vulnerability experienced by transgender women. However, findings should not be generalized beyond sub-Saharan Africa or the study period. Clinicians should interpret these results as associations rather than causal mechanisms and avoid inferring specific risk factors solely from prevalence data.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
INTRODUCTION: The Global AIDS Strategy 2021-2026 calls for equitable access to HIV services for all populations. Transgender people have been marginalized and experience disproportionate risk of HIV infection in sub-Saharan Africa (SSA) and data to guide HIV programmes are severely limited. Surveillance data among cisgender men who have sex with men (cis-MSM) are comparatively abundant. We assessed whether HIV prevalence among cis-MSM was correlated with HIV prevalence among transgender women. METHODS: Data from key population surveys conducted in SSA between 2010 and 2022 were identified from existing databases and survey reports. Studies that collected HIV prevalence data among both transgender women and cis-MSM populations were analysed with random effect meta-analysis to estimate the ratio of HIV prevalence among cis-MSM:transgender women. RESULTS: Twenty-one studies were identified encompassing 8476 transgender women and 24 102 cis-MSM. Median HIV prevalence among transgender women was 23.5% [interquartile range (IQR) 11.5-39.8%] and 16.2% (IQR 8.1-26.8%) among cis-MSM. HIV prevalence among transgender women was 50% higher than in cis-MSM [prevalence ratio 1.48, 95% confidence interval (CI) 1.25-1.76]. HIV prevalence among transgender women was highly correlated with year/province-matched HIV prevalence among cis-MSM ( R2  = 0.60), but poorly correlated with year/province-matched total population HIV prevalence ( R2  = 0.01). CONCLUSION: Transgender women experience a significantly greater HIV burden than cis-MSM in SSA, underscoring the need for HIV services addressing the disproportionate vulnerability experienced by transgender women. Further bio-behavioural surveys focused on determinants of HIV infection, treatment uptake, and risk behaviours among transgender people, distinct from cis-MSM, will improve understanding of HIV risk and vulnerabilities.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.